Impact of Stopping Thiopurines Under Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: A Population-Based Study
Clinical Gastroenterology and Hepatology · 2026-04
DOI: 10.1016/j.cgh.2026.04.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Jeongkuk Seo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Chung-Ang University, Ministry of Science and ICT, South Korea, National Research Foundation of Korea.
Abstract (Originalsprache)
BACKGROUND & AIMS: The impact of stopping thiopurines after escalating to treatment with an anti-tumor necrosis factor agent in patients with inflammatory bowel disease is currently unclear. We aimed to assess the impact of stopping vs continuing thiopurines after initiating anti-tumor necrosis factor therapy. METHODS: In this retrospective cohort study, we analyzed data from the Korean National Health Insurance claims database of 6235 patients with ulcerative colitis or Crohn's disease on thiopurines, who started anti-tumor necrosis factor treatment between 2007 and 2020. Patients were classified based on thiopurine discontinuation within 90 days of initiating anti-tumor necrosis factor therapy. The primary outcome was a composite of new corticosteroid use, inflammatory bowel disease-related hospitalization, or intestinal surgery. RESULTS: Among the eligible patients, 1900 (30.5%) had ulcerative colitis, and 4335 (69.5%) had Crohn's disease; 429 (22.6%) patients with ulcerative colitis and 913 (21.1%) patients with Crohn's disease discontinued thiopurines within 90 days. In the ulcerative colitis group, multivariable analysis demonstrated a modest increase in the risk of new corticosteroid use (adjusted hazard ratio, 1.18; 95% confidence interval, 1.04-1.35) and the composite outcome (adjusted hazard ratio, 1.20; 95% confidence interval, 1.05-1.37) among patients who discontinued thiopurines. In contrast, no independent association was observed between thiopurine discontinuation and adverse clinical outcomes in the Crohn's disease group. These results remained consistent in sensitivity analyses using a 6-month landmark (ulcerative colitis composite outcome: adjusted hazard ratio, 1.20; 95% confidence interval, 1.04-1.38). CONCLUSIONS: Discontinuing thiopurines after initiating anti-tumor necrosis factor therapy was associated with a modest increase in the risk of adverse clinical events in patients with ulcerative colitis. This warrants careful risk-benefit assessment before stopping thiopurines after escalation to anti-tumor necrosis factor therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
- Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea; Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, S…
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: kimyejee@amc.seoul.kr.
Förderung
- Chung-Ang University
- Ministry of Science and ICT, South Korea
- National Research Foundation of Korea
Zitieren
APA
Seo, J., Kim, S., Hong, S. W., Hwang, S. W., Park, S. H., Yang, D. H., Byeon, J. S., Myung, S. J., Kim, Y. J., & Ye, B. D. (2026). Impact of Stopping Thiopurines Under Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: A Population-Based Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.017
Vancouver
Seo J, Kim S, Hong SW, Hwang SW, Park SH, Yang DH, et al. Impact of Stopping Thiopurines Under Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: A Population-Based Study. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.04.017
BibTeX
@article{Seo2026,
author = {Seo, Jeongkuk and Kim, Seonok and Hong, Seung Wook and Hwang, Sung Wook and Park, Sang Hyoung and Yang, Dong-Hoon and Byeon, Jeong-Sik and Myung, Seung-Jae and Kim, Ye-Jee and Ye, Byong Duk},
title = {Impact of Stopping Thiopurines Under Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: A Population-Based Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.04.017}
}
EUVIMED